Pfiz­er’s lat­est copy­cat could put the squeeze on Roche — again

Pfiz­er $PFE is bar­rel­ing for­ward on its plans to recre­ate Roche’s stal­wart can­cer drugs, an­nounc­ing pos­i­tive da­ta this morn­ing for its Rit­ux­an copy­cat called PF-05280586. Con­sid­er­ing Roche’s $RHH­BY re­cent back­lash to biosim­i­lar com­pe­ti­tion, it’s pos­si­ble that Pfiz­er will con­tin­ue to poke the rather liti­gious bear.

Like you’d want to see from a biosim­i­lar, PF-05280586’s tri­al met its pri­ma­ry end­point and showed equiv­a­lence in over­all re­sponse rate for pa­tients with CD20-pos­i­tive fol­lic­u­lar lym­phoma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA